Nuclear Imaging for Subtype Diagnosis of Primary Aldosteronism
Status: Recruiting
Location: See location...
Intervention Type: Biological
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
This study is to evaluate the accuracy of a novel radiopharmaceutical tracer, para-chloro-2-\[18F\]fluoroethyl etomidate (CETO), used with positron emission tomography (PET) and computed tomography (CT), as a way to subtype unilateral vs. bilateral forms of Primary Aldosteronism, compared to AVS as a reference gold standard.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Individuals with hypertension
• Individuals with an elevated screening adrenal renin ratio (ARR)
• Individuals with or without spontaneous or diuretic-induced hypokalemia, and/ or plus a discrete adrenal nodule or nodules (1 cm or greater) with concordant lateralization on AVS.
Locations
Other Locations
Canada
University of Calgary
RECRUITING
Calgary
Contact Information
Primary
Alexander Leung, MD
aacleung@ucalgary.ca
(403) 955-8358
Time Frame
Start Date: 2023-01-01
Estimated Completion Date: 2026-06-30
Participants
Target number of participants: 30
Treatments
Experimental: CETO
The consented participants will receive the \[18-F\] CETO through the IV and a PET/CT scan afterwards.
Related Therapeutic Areas
Sponsors
Leads: University of Calgary